Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Relapsing Pleural Mesothelioma
NCT06840834Phase 2Recruiting
- Sponsor
- IFCT
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in pleural mesothelioma, sponsored by IFCT. Primary endpoint: Disease Control Rate at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT06840834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840834.